Stockscreener 앱 받기
99.78
3.28%
-3.38
시간 외 거래:
99.78
전일 마감가:
$103.16
열려 있는:
$102.95
하루 거래량:
641.65K
Relative Volume:
0.86
시가총액:
$6.66B
수익:
$136.86M
순이익/손실:
$-168.69M
주가수익비율:
-35.51
EPS:
-2.81
순현금흐름:
$-113.49M
1주 성능:
+1.74%
1개월 성능:
-2.74%
6개월 성능:
+1.09%
1년 성능:
+72.81%
1일 변동 폭
$97.15
$103.52
1주일 범위
$97.15
$104.50
52주 변동 폭
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
99.78 | 6.88B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Is Rhythm Pharmaceuticals Inc vulnerable to short sellersWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Royal Bank Of Canada Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Moderate Buy - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith Sells 3,569 Shares - MarketBeat
Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus
Rhythm pharmaceuticals CFO Smith sells $805k in shares By Investing.com - Investing.com UK
Rhythm pharmaceuticals CFO Smith sells $805k in shares - Investing.com
Expert Outlook: Rhythm Pharmaceuticals Through The Eyes Of 11 Analysts - Benzinga
Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market - Benzinga
Rhythm Pharmaceuticals Seen Poised for Growth in Rare Genetic Obesity, RBC Says - marketscreener.com
RBC Capital Initiates Coverage on Rhythm Pharmaceuticals With OutperformSpeculative Risk Rating, $145 Price Target - marketscreener.com
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
RBC Capital Initiates Coverage on RYTM with 'Outperform' Rating - GuruFocus
RBC Capital Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - Nasdaq
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating - MarketBeat
Readystate Asset Management LP Sells 16,301 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
RBC Capital initiates Rhythm Pharmaceuticals stock with outperform rating - Investing.com
How The Rhythm Pharmaceuticals RYTM Story Is Shifting With Imcivree Revenue And New Targets - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) to Release Quarterly Earnings on Wednesday - MarketBeat
IPO Launch: Can Rhythm Pharmaceuticals Inc expand into new marketsJuly 2025 Momentum & Technical Confirmation Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - The Manila Times
Rhythm Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviews - MSN
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A 44% Upside Potential in the Biotech Space - DirectorsTalk Interviews
Trading Systems Reacting to (RYTM) Volatility - Stock Traders Daily
Rhythm Pharmaceuticals Eyes March 20 HO PDUFA, Highlights IMCIVREE Growth at Guggenheim Conf. - MarketBeat
Will Rhythm Pharmaceuticals Inc. stock remain a Wall Street favoriteJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - mfd.ru
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness - Sahm
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $272,755.26 in Stock - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith Sells 1,592 Shares - MarketBeat
Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity - TipRanks
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Hunter Smith Sells 2,713 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock - MarketBeat
Rhythm Pharmaceuticals at Guggenheim Summit: Expanding Horizons in Biotech By Investing.com - Investing.com Canada
Is Rhythm Pharmaceuticals Inc. stock risky to hold now2025 Price Targets & Long-Term Growth Stock Strategies - mfd.ru
Earnings Risk: Is Rhythm Pharmaceuticals Inc currently under institutional pressure2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Candriam S.C.A. Lowers Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
What are Rhythm Pharmaceuticals Inc.’s recent SEC filings showingChart Signals & Community Consensus Trade Alerts - mfd.ru
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Bond Watch: Will Rhythm Pharmaceuticals Inc benefit from green energy policies2025 Growth vs Value & Short-Term Trading Alerts - baoquankhu1.vn
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock - Investing.com Australia
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $358,588.86 in Stock - MarketBeat
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals' CFO Hunter C. Smith to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit - GlobeNewswire
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by New York State Common Retirement Fund - MarketBeat
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
WCM Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
This High-Flying Growth Stock Is Hiding in Plain Sight - Finviz
Federated Hermes Inc. Has $174.50 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.89%
자본화:
|
볼륨(24시간):